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ABSTRACT 
A key challenge in the development of novel chemotherapeutics is the design of molecules 
capable of selective toxicity to cancer cells. Antibodies have greater target specificity compared 
to small molecule drugs, but most are unable to penetrate cells, and predominantly target 
extracellular antigens. A nuclear-penetrating anti-DNA autoantibody isolated from the MRL/lpr 
lupus mouse model, 3E10, preferentially localizes to tumors, inhibits DNA repair, and 
selectively kills cancer cells with defects in DNA repair. A murine divalent single chain variable 
fragment of 3E10 with mutations for improved DNA binding affinity, 3E10 (D31N) di-scFv, has 
previously been produced in P. pastoris and yielded promising pre-clinical findings, but is 
unsuitable for clinical testing. The present study reports the design, expression and testing of a 
panel of humanized 3E10 (D31N) di-scFvs, some of which contain CDR substitution. These 
variants were expressed in a modified CHO system and evaluated for their physicochemical 
attributes and ability to penetrate nuclei to selectively cause DNA damage accumulation in and 
kill cancer cells with DNA repair defects. Secondary structure was conserved and most variants 
retained the key characteristics of the murine 3E10 (D31N) di-scFv produced in P. pastoris. 
Moreover, several variants with CDR substitutions outperformed the murine prototype. In 
conclusion, we have designed several humanized variants of 3E10 (D31N) di-scFv that have 
potential for application as monotherapy or conjugates for targeted nuclear drug delivery. 
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1. Introduction 
     Challenges associated with the low therapeutic index and associated off-target toxicity of 
small molecule chemotherapy drugs has given rise to an ever-expanding portfolio of antibodies 
targeted against cancer antigens. The past decade has seen an exponential growth of antibodies 
used in the treatment of malignancies, and more recently, with gains in linker chemistry and an 
understanding of antibody properties, antibody-drug conjugates [1] have emerged as a viable 
platform to improve chemotherapeutic outcomes. While such antibody therapeutics have been 
successful, their utility in targeting intracellular antigens has been limited due to their inability to 
directly penetrate cells and access intracellular compartments [2]. Hence, most antibodies in 
clinical development are against extracellular target antigens [3].  
     Autoantibodies reactive to intracellular host antigens are associated with inflammation and 
poor prognosis in autoimmune diseases [4, 5]. Most cell-penetrating autoantibodies are toxic, but 
3E10, an anti-DNA autoantibody isolated from the MRL/lpr lupus mouse model, has been found 
to penetrate nuclei in a manner that is non-toxic to normal cells [6]. 3E10 inhibits DNA single 
and double-strand break (DSB) repair and is synthetically lethal to cancer cells defective in DNA 
repair machinery (e.g. BRCA1/2 and PTEN mutations), but spares DNA repair-proficient cells 
[7, 8]. Additionally, 3E10 is attracted to DNA released by necrotic cancer cells, and 
preferentially accumulates at tumor sites in vivo suggesting its use in cancer therapy [7]. 
     Previously a divalent 3E10 single chain variable fragment with improved DNA binding 
affinity (3E10 (D31N) di-scFv), hereafter referred to as di-scFv was evaluated [9]. Di-scFv lacks 
the unnecessary 3E10 Fc region that has potential to contribute to non-specific toxicity. Di-scFv 
has yielded promising pre-clinical results both as a monotherapy against DNA repair-deficient 
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tumors and as a drug delivery ligand [9, 10], but due to C-terminal Myc and His6 tags is 
unsuitable for human use. Herein, we report the design, expression and evaluation of a panel of 
novel humanized di-scFv variants that lack any tags with a view to utilizing them as novel 
anticancer agents or drug delivery ligands. 
 
2. Material and Methods 
2.1. Reagents 
     Unless otherwise stated, all cell culture reagents, protein L, and primary and secondary 
antibodies were obtained from Invitrogen (Carlsbad, CA, USA).  
2.2. In silico humanization of di-scFv 
     Murine di-scFv with C-terminal Myc and His6 tags was previously designed and evaluated 
using a combination of in vitro and in vivo studies [9]. Di-scFv lacks an Fc, and therefore efforts 
to humanize di-scFv focused on VL and VH domains. Sequence alignments between the murine 
di-scFv VL and VH, and human germline sequences identified the optimal acceptor framework 
for di-scFv VL and VH. J-segments were also selected. In silico CDR-grafting was subsequently 
performed wherein amino acids in the di-scFv framework sequence were changed to that of the 
human sequence. Subsequently, a series of back-mutations were selected to maintain di-scFv 
function by preserving the VL-VH interface and Vernier zone. Following completion of CDR-
grafting and selection of back-mutations, the resulting sequences were immunoprofiled against 
85 HLA class II allotypes to identify Th epitopes. Sequences were also screened for potential 
post-translational modification (PTM) sites. In some cases, substitutions within CDRs were 
permitted to reduce immunogenicity and screen for effects on cellular penetration. Ultimately, a 
panel of six distinct humanized VL (three containing a CDR change, and three without CDR 
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changes) and six VH (three containing a CDR change and three without CDR changes) were 
selected, and 16 different combinations of these fragments were selected for expression 
(supplementary information Table S1). 
 
2.3. Protein expression & purification 
     The murine (yeast) di-scFv prototype was expressed in P. pastoris and purified using 
approaches described elsewhere [9]. For novel di-scFv prototype expression, cDNAs encoding 
the murine di-scFv sequence or each of the 16 humanized variants were synthesized and sub-
cloned into a proprietary CHO expression vector. Stable CHO cell pools expressing the antibody 
fragments were generated in CD-CHO media (Invitrogen) and a base feed utilized for the 
expression culture (bolus feed was added on day four, and the cultures harvested at day eight). 
The medium was subsequently centrifuged to remove cellular matter, and filtered using a 0.22 
µm pore-sized filter. Purification of di-scFv variants was achieved using a two-step process 
including ion exchange chromatography and NaCl gradient elution (over 20 column volumes) on 
an Äkta system equipped with a HiTrap Capto S column at a (5 mL/min flow rate) (GE 
Healthcare). Following purification, samples were concentrated using Amicon Ultra-15 filters 
(Millipore) and subjected to analysis of monomeric purity using SEC-HPLC (see supplementary 
information, Table S2). 
2.4. Cell lines 
     A matched pair of isogenic BRCA2-SUR¿FLHQW DQG -GH¿FLHQW '/'-1 colon cancer cells 
(Horizon Discovery Ltd) were grown in RPMI-1640 supplemented with 10% v/v FBS. PTEN-
deficient U251 and PTEN-proficient U251-PTEN glioma cells were a gift from Peter Glazer and 
grown in high glucose DMEM supplemented with 10% v/v FBS. PTEN induction in U251-PTEN 
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was achieved by the addition of 400 µg/mL G418, 2 Pg/mL blasticidin, and 1 µg/mL 
doxycycline as described elsewhere [9]. PTEN-deficient U87 glioma cells were grown in high-
glucose DMEM containing 10% v/v FBS. 
 
2.5. Sample preparation  
     For phospho-53BP1 foci formation and trypan blue exclusion assays, di-scFv variant samples 
were exchanged into respective growth media (i.e. DMEM or RPMI 1640) and sample 
concentration was quantified using the Bradford assay. Subsequently, SDS-PAGE with 
Coomassie staining (Invitrogen) was performed to confirm di-scFv stability in the samples. All 
samples were filter sterilized using a 0.2 µm pore-sized syringe filter, and the concentration of 
di-scFv in PBS was quantified using absorbance at 280 nm with a Nanodrop 1000 (Thermo 
Fisher Scientific). 
 
2.6. In Silico Prediction of Secondary Structure and Disorder Tendency.  
Sequence-based prediction of di-scFv secondary and higher order structure was performed using 
Phyre 2 [11]. To predict short and long-range disorder, sequence data for murine and humanized 
di-scFv variants E and J was inputted into IUPRED, and the disorder tendency score for each 
residue was generated [12, 13]. 
 
2.7. Circular Dichroism 
     The secondary structure of murine di-scFv and variants E and J was examined using a 
Chirascan spectrafluorimeter (Applied Photophysics). Samples analyzed by CD were buffer 
exchanged into a 10 mM pH 6 potassium phosphate buffer (MWCO 10 kDa) prior to analysis. 
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Individual CD spectra were collected between 260-190 nm at 20 °C using a 1 mm path length 
quartz cuvette. A sampling time of one second, step size of 1 nm and bandwidth of 1 nm was 
used for each measurement. Buffer spectra were also collected using the same data acquisition 
parameters, and subtracted from sample spectra. The resultant data was converted to molar 
ellipticity and mean residue ellipticity. Additionally, raw CD data (mdeg) was inputted into 
CAPITO [14] and BESTSEL [15] to determine the approximate secondary structure content of 
samples examined. 
 
2.8. Cell penetration assays  
     DLD-1 cells cultivated in 96-well plates were treated either with control vehicle or 10 µM di-
scFv variant(s) for 60 minutes at 37 °C. Subsequently, treated cells were washed with PBS twice, 
¿[HG ZLWK SUH-chilled 100% ethanol. Fixed cells were blocked, incubated with protein L 
(Invitrogen) and probed with a chicken anti-protein L primary antibody (Invitrogen). 
Subsequently, cells were treated with an Alexa Fluor 555-conjugated goat anti-chicken antibody 
(Invitrogen) for one hour at ambient temperature. A DAPI counterstain was applied to aid 
qualitative assessment of di-scFv localization. All timings and reagents were kept constant for 
analysis of cell penetration. 
 
2.9. Assessment of phospho-53BP1 (P53BP1) foci formation 
     In order to assess P53BP1 foci formation, U251 PTEN proficient and deficient cells were 
cultivated in 96 well plates overnight prior to treatment with di-scFv. Subsequently, cells were 
treated either with DMEM containing 10 µM di-scFv variant or DMEM (control), and incubated 
for 24 hours at 37 °C. Following treatment, cells were fixed, blocked, and incubated overnight 
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with a rabbit anti-P53BP1 primary antibody (Cell signaling technology). Cell monolayers were 
subsequently probed with an Alexa Fluor 555-conjugated goat anti-rabbit IgG secondary 
antibody (Life technologies) and counterstained with DAPI prior to image acquisition. 
 
2.10. Image acquisition & data analysis 
     Cell penetration assays. Images of di-scFv cell penetration were acquired using a Zeiss 710 
confocal microscope (Advanced Microscopy Group) using the 543 nm (Alexa Fluor 555) and 
MaiTai laser (DAPI, blue) lines. Several representative fields of view at a 40X magnification (c-
Apochromat 40x/1.2NA water-immersion objective lens) were acquired for each condition. 
Subsequently, multiple channel images were merged using Image J (NIH, Bethesda, USA). All 
image acquisition parameters were maintained between samples, and acquired images were 
deconvoluted in Huygens (version 17.04.1p0). The fluorescence intensity of staining for each 
cell was analyzed using the Image J (version 1.51n) particle analysis function. Following image 
thresholding, the fluorescence intensity of each cell was determined and resultant data plotted as 
box plots in Origin (version b9.4.0.220). 
     P53BP1 foci. Images were acquired with an EVOS fl digital fluorescence microscope using 
the DAPI and RFP (red fluorescent protein) filtersets. Several representative fields of view were 
acquired at a 40X magnification for each treatment and exported as 8-bit TIFF files. The number 
of foci per cell was determined in Cell ProfilerTM (Broad Institute, MA, USA), and only foci co-
localized with the DAPI stain were counted. 
 
2.11. Trypan blue exclusion assay  
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     Isogenic BRCA2 proficient and deficient DLD-1 cells, and PTEN-deficient U87 cells were 
cultivated in 96-well plates and treated with either medium (control), or medium containing 10 
µM di-scFv variant. Subsequently, cells were incubated for one week at 37 °C, were assessed 
using optical microscopy following treatment, trypsinized and treated with trypan blue. Cells 
were manually counted in a grid, and the number of viable (white) and non-viable (blue) cells 
quantified. 
 
2.12. Statistical analysis.  
     All data are represented as mean ±standard error (SEM). Unless otherwise stated, a two-tailed 
Student¶V t-test assuming unequal variances was utilized to determine P values and a P <0.05 was 
deemed as statistically significant. 
 
Results  
3.1. Expression of di-scFv variants 
     Humanized di-scFv 3E10 variants were expressed with varying yields using a modified CHO 
expression system. Resultant growth medium containing di-scFv variant was subjected to 
clarification, followed by ion exchange purification. Subsequently, all purified di-scFv was 
exchanged into pH 7 phosphate-buffered saline and retained for characterization. All di-scFv 
variants were analyzed by SDS-PAGE. For all lanes, a band corresponding to di-scFv was 
observed at approximately 54 kDa (see supplementary information, Figure S1). 
 
3.2. Analysis of di-scFv variant secondary structure 
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     Following assessment of di-scFv expression and purity in generated stable cell pools, the 
secondary structure of the variants was predicted using in silico models. Resultant outputs of 
comparison between di-scFv E, di-scFv J, and the murine prototype are presented (Figure 1A). 
In parallel, CD analysis of these di-scFv fragments was performed (10 mM phosphate buffer, pH 
7), to determine whether features of the murine prototype were conserved in the new di-scFv 
variants (Figure1B-C). Evaluation of in silico data and rendering of secondary structure 
suggested no significant change in secondary and higher order structure following humanization 
of the di-scFvs. This was further confirmed by circular dichroism, with minima evident at 195-
200 nm for all di-scFvs. However, in the case of the novel variants, small maxima (positive 
peak) appeared at approximately 218 nm. Analysis of CD spectra in BESTSEL resulted in 
assignment of ß-sheet and unassigned secondary structure (consistent with disorder) for all 
spectra. Similar structural profiles were assigned using CAPITO, albeit with higher NRMSDs. 
These observations suggest the potential presence of polyproline helices typically associated 
with intrinsically-disordered or unfolded proteins [16] and are consistent with the proportion of 
unassigned secondary structure elements (~30%) from the Phyre in silico simulations that 
usually dominate CD spectra [17]. Sequence-based prediction of disorder tendency was further 
assessed using the IUPRED sequence-based prediction platform [13]. Comparison of output 
generated from disorder tendency scores for di-scFvs E and J versus murine di-scFv revealed 
overlap across the sequences examined (Figure 1D-E). This suggests that the long- and short-
range disorder tendency for these fragments is broadly similar. Overall, evaluation of secondary 
structure using experimental and in silico data suggested the absence of structural changes 
following humanization and sequence modification. 
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Figure 1 placeholder 
 
3.3. Evaluation of nuclear penetration by the di-scFv variants 
     Previous studies on the cell-penetrating activity of murine (yeast) di-scFv relied on the C-
terminal Myc tag for detection. The new variants lacked such tags, and consequently an alternate 
detection approach was required. Protein L binds most kappa antibody variable domains and was 
confirmed to aid detection of di-scFv in a western blot (Figure S2). Hence, protein L detection 
was used to compare the abilities of the di-scFv variants to penetrate DLD-1 cell nuclei. Most di-
scFv fragments accumulated in cell nuclei, except for di-scFvs I, K and P that were observed to 
contain limited or no nuclear di-scFv localization. Individual Alexa 555 and DAPI confocal 
images from protein L immunostaining cells are presented in Figure 2. To assess relative 
heterogeneity of cellular penetration by di-scFv variants, the measured fluorescence intensity 
obtained from confocal image analysis was plotted for cell populations incubated with each 
variant (Figure 2, bottom). Most variants, except for di-scFvs I, K and P, exhibited significant 
staining and equivalent profiles in fluorescence intensity. 
 
Figure 2 placeholder 
 
3.4. Di-scFv variants cause accumulation of P53BP1 foci in PTEN-deficient cells 
Phosphorylated 53BP1 foci, reporters of DNA double strand breakage (DSB), are transiently 
observed in normally-dividing cells proficient in DNA damage repair, and are regarded as a 
mediator of DNA DSB repair [19]. Murine di-scFv was previously shown to cause DSB 
accumulation in homology-directed repair (HDR)-deficient cancer cells. To assess the impact of 
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the new di-scFvs on DNA damage, P53BP1 foci accumulation was assessed following a 24 hour 
incubation with murine (yeast) di-scFv or variants E, G, H, I, J, K, L and M in PTEN-deficient 
and proficient U251 cells). Example cells from PTEN-proficient and deficient cells and 
quantification of number of foci per cell are presented in Figure 3. For nuclear-penetrating 
variants (E, G, H, J, L, and M) significant foci accumulation was observed following 24-hours in 
PTEN-deficient U251 glioblastoma cells (ANOVA, two-tailed, P=0.04). Conversely, in PTEN-
expressing cells, no notable difference in P53BP1 foci numbers was observed following 
treatment (ANOVA, two-tailed, P>0.5). Overall, these data suggest that nuclear-penetrating di-
scFv variants retain the ability to inhibit base excision repair (BER) and HDR in PTEN-deficient 
cells [9]. Variants incapable of localizing to cell nuclei (di-scFvs I and K) did not yield any 
significant impact on P53BP1 foci, indicating that nuclear penetration is a pre-requisite for foci 
accumulation. 
 
Figure 3 placeholder 
 
3.5. Di-scFv variants are selectively toxic to cells with deficiencies in DNA damage repair 
     To establish whether the new variants retain selective toxicity to HDR-deficient cancer cells, 
matched BRCA2-proficient and deficient DLD-1 cells and PTEN-deficient U87 cells were 
treated with the murine (yeast) di-scFv and variants G, J, L, and M for seven days, followed by 
trypan blue exclusion assay to determine the percentage of viable cells. Brightfield micrographs 
captured prior to trypan blue staining revealed prominent changes in cell morphology and a lack 
of proliferation for treated BRCA2-deficient cells, but BRCA2-proficient cells were unaffected 
by treatment (Figure 4A). Analysis of cell viability demonstrated that di-scFv variants were 
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toxic to BRCA2-deficient DLD-1 cells (Figure 4B) and PTEN-deficient U87 cells (Figure 4C) 
when compared to control, but not to BRCA2-proficient DLD-1 cells.  
 
Figure 4 placeholder 
 
 
4. Discussion 
     A combination of advancements in antibody characterization, novel linker chemistries, and 
fine-tuning of antibody fragments has opened the door to re-engineering of cell-penetrating 
autoantibodies capable of bypassing biological barriers to tumor drug delivery. Cell-penetrating 
autoantibodies exemplified by DNA-damaging autoantibody, 3E10, are compelling candidates 
for further development. 3E10 preferentially localizes to tumors in vivo and exerts single-agent 
effects on DNA repair-deficient cancer cells, while sparing normal cells. However, it has 
previously been unknown whether 3E10 would retain its key functionality once humanized for 
clinical development. We have demonstrated the successful design and expression of humanized 
di-scFvs, and found that most have equivalent or enhanced activity relative to the yeast murine 
di-scFv prototype.  
     The di-scFv variants were subjected to a functional assay cascade beginning with an 
evaluation of cell penetration ability. Most di-scFv variants exhibited nuclear localization, except 
for di-scFvs I, K, and P that demonstrated limited or no nuclear staining in DLD-1 cells and were 
subsequently found to have no significant impact on P53BP1 foci accumulation. Intriguingly, 
broader heterogeneity in nuclear penetration was observed with some variants in comparison to 
others as represented in population data (Figure 2). Observed differences in maximum staining 
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intensity across the panel of variants examined may be related to differential affinity for DNA 
and exploitation of ENT2 transporter trafficking [20]. An assessment of the mechanism of cell 
penetration is outside the scope of the present work, and further studies are required to elucidate 
the sequence of events leading to internalization and trafficking of 3E10 to cell nuclei. 
To confirm that the di-scFv variants exhibited similar or enhanced effects on DSB accumulation 
(P53BP1 foci) relative to murine di-scFv, U251 cells (PTEN proficient and deficient) were 
treated with a select panel of di-scFv variants for 24 hours. Consistent with previous 
observations reported by Noble et al [9] on the yeast murine di-scFv, significant accumulation of 
DSBs was found in the treated PTEN-deficient cells, and no DSB accumulation was observed in 
PTEN-proficient cells.  
Murine di-scFv expressed in yeast has previously been shown to be synthetically lethal to HDR-
deficient cancer cells but to spare cells with intact HDR [9]. Due to limitations relating to 
quantities of di-scFv variants available for initial testing, screens for toxicity to BRCA2- and 
PTEN-deficient cancer cells were performed in a small scale 96-well format trypan blue 
exclusion assay. Future evaluation of lead candidates and other novel di-scFvs will include 
automated cell proliferation assays and clonogenic assessment of cell survival over various 
incubation periods in additional cell lines with known HDR defects. 
     In silico sequence-based prediction of secondary structure revealed no significant changes 
between the novel di-scFv variants and the murine (yeast) prototype. In all cases, an unassigned 
or disordered secondary structure proportion (up to 40%) was observed in variants examined. 
Further assessment of the sequence, using IUPRED short- and long-range disorder tendency 
prediction, yielded overlapping profiles for the di-scFvs examined. CD analysis of di-scFv 
samples indicated a similar overall profile shape, with the presence of minima at 195-200 nm 
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(Figure 1). In the case of humanized variants, a small maximum was observed at 218 nm. 
Observed differences in molar ellipticity may be attributed to differences in analyte monomeric 
purity rather than structural differences. Overall, in silico and CD analyses indicate the presence 
of some ß-sheet structure consistent with antibodies, and disorder associated with unassigned in 
silico allocations and CD spectra.  
     Intrinsically-disordered proteins (IDPs) exist in conformationally-flexible states lacking 3D 
structure under native physiological conditions. A more in-depth analysis of the molecular 
machinery implicated in the trafficking of 3E10 to the nucleus and ligand binding studies are 
required to understand processes that confer functionality to 3E10. Understanding such structural 
determinants may shed light on the pathophysiology of cell-penetrating autoantibodies, aid target 
discovery for SLE, and contribute to the design of effective targeting sequences. 
     In conclusion, we have demonstrated the successful humanization of 3E10-derived di-scFv 
fragments with conserved structural properties and equivalent or enhanced in vitro activity, with 
a view to developing novel therapeutics against HDR-deficient tumors. This work has led to the 
selection of a lead candidate for progression to pre-clinical development. Further work is 
underway to evaluate in vivo efficacy of these antibodies as monotherapies in tumor-bearing 
models and their potential as targeting ligands for nuclear drug delivery. 
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Figure Legends 
Figure 1 In silico renditions of Phyre predicted structures for di-scFv in Jmol (A), corresponding 
molar ellipticity, (B) mean residue ellipticity measured by far UV circular dichroism (C), and 
IUPRED in silico predictions of long (D) and short-range (E) predicted disorder tendency [18]. 
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Figure 2 Cellular penetration assay of di-scFv variants and corresponding box plots. DLD-1 
cells were treated with either control vehicle or 10 µM di-scFv variant. Following treatment, 
cells were immunostained with protein L, anti-protein L primary antibody and an Alexa Fluor 
555 conjugated secondary antibody (and a DAPI counterstain). Box plots represent nuclear 
IOXRUHVFHQFH LQWHQVLW\ GHWHUPLQHG IURP WKH DQDO\VLV RI FRUUHVSRQGLQJ FRQIRFDO LPDJHV Ɣ
represents the mean intensity, and the horizontal box lines represent the median, lower and upper 
quartiles. The whiskers represent outliers. 
Figure 3 Di-scFv variants cause accumulation of DSBs in PTEN-deficient U251 cells. 
Treatment with di-scFv variants resulted in accumulation of phospho-53BP1 foci (pink) in 
PTEN-deficient U251 cells (blue, DAPI counterstain). Mean number of measured P53BP1 foci 
per cell determined following treatment with di-scFv variants (top), and example U251-PTEN 
(upper bottom panel) and U251 (lower bottom panel) cell images following a 24 hour incubation 
with 10 µM di-scFv variants as visualized by immunofluorescence. PTEN-deficient U251 cells 
demonstrate an accumulation in P53BP1 foci following treatment with di-scFv variants. 
 
Figure 4 Di-scFv variants are toxic to HDR-deficient cancer cells. A representative field of view 
of DLD-1 parental and BRCA 2- deficient cells following treatment with RMPI (control) or 10 
µM di-scFv_G for seven days (A). Percent viability relative to control, measured by trypan blue 
exclusion, for BRCA2-proficient and deficient DLD-1 cells (B) and PTEN-deficient U87 cells 
incubated with selected di-scFv variants for seven days (C).  
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